94 search results for: type 2 inflammation

<b>Type</b> <b>2</b> <b>Inflammation</b> Is a Significant Driver of Pediatric Severe Asthma
Infographic

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Pulmonology
Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients
View more
ADVENT On Air | Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in COPD
Podcast

ADVENT On Air | Role of Type 2 Inflammation in COPD

Pulmonology
Drs Stephanie Christenson and Jean Bourbeau explore the role of type 2 inflammation in Chronic Obstructive Pulmonary Disease (COPD).
View more
Itch: The Common Thread in Dermatological <b>Type</b> <b>2</b> <b>Inflammation</b> (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
Itch: The Common Thread in Dermatological <b>Type</b> <b>2</b> <b>Inflammation</b> (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
The Impact of <b>Type</b> <b>2</b> <b>Inflammation</b> on the Neuroimmune Axis in AD
expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

Dermatology
Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.
View more
The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Multiple Disease Trajectories
Infographic

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Dermatology
How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.
View more
ERS <b>2</b>0<b>2</b>4 | Unraveling the Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in COPD
expert video

ERS 2024 | Unraveling the Role of Type 2 Inflammation in COPD

Pulmonology
Professor Mona Bafadhel presents a comprehensive overview of type 2 inflammation in COPD, exploring its underlying mechanisms, clinical manifestations, and implications for patient outcomes.
View more
ERS <b>2</b>0<b>2</b>4 | A Breath of Fresh Air: A Greater Understanding of COPD With <b>Type</b> <b>2</b> <b>Inflammation</b>
expert video

ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

Pulmonology
Professors Henrik Watz, Mona Bafadhel, and Alberto Papi discuss the pathophysiology of COPD with type 2 inflammation and review current and emerging biologic therapies
View more
Why targeting <b>Type</b> <b>2</b> <b>Inflammation</b> is important in the treatment of skin diseases like AD, PN and CSU
expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

Dermatology
Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.
View more
IRS-ISIAN <b>2</b>0<b>2</b>4 | Targeting <b>Type</b> <b>2</b> <b>Inflammation</b>: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP
expert video

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

Rhinology
Prof. Joaquim Mullol reports on biologic improvements in sense of smell and nasal congestion in patients with and without a history of endoscopic sinus surgery.
View more
<b>2</b>0<b>2</b>5 ADVENT Forum | Joint Plenary Session: A View into the Life of Our Patients Video
expert video

2025 ADVENT Forum | Joint Plenary Session: A View into the Life of Our Patients Video

Type 2 Inflammation
This cross-TA plenary session addressed challenges in type 2 inflammation-driven diseases. Esteemed faculty, including Profs Klaus Rabe, Sharon Dell, Anju Peters, Milli Gupta, Eric Simpson, Stella Lee, and moderator Oscar Palomares, discussed strategies to enhance quality of life, reduce disease burden, and prioritize patient-centered care.
View more
How Does Protective <b>Type</b> <b>2</b> Immunity Become Harmful <b>Type</b> <b>2</b> <b>Inflammation</b>?
expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

Dermatology
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region